PATENT CLAIM ANALYSIS

Application Number: 15933532
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-07
Patent Classification: ["514", "275000"]

Abstract:
This disclosure provides compounds and compositions and methods of using those compounds and compositions to treat diseases and disorders associated with excessive transforming growth factor-beta (TGFβ) activity. This disclosure also provides methods of using the compounds in combination with one or more cancer immunotherapies.

Claim (Index 9):
The method of  claim 6 , wherein the antibody therapy comprises an antibody selected from the group consisting of Pidilizumab, Alemtuzumab, Bevacizumab, Brentuximab vedotin, Cetuximab, Gemtuzumab ozogamicin, thritumomab tiuxetan, Ipilimumab, Ofatumumab, Panitumumab, Rituximab, Tositumomab, and Trastuzumab.

Metadata:
- Claim Count in Document: 53.0
- Percentile: 90.0
- Lexical Diversity: 1.41176
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15109013', '15067605', '11292358', '15183486', '11332674']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7893368605666337
- 35 USC 102 Novelty (BERT): 0.5343134420258612
- Combined Prediction Score: 0.7638345187125564
- Mean Citation Score: 285.9536720000001
- Max Citation Score: 348.4242
- Similarity Product: 234.00986967816348

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test